Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have received a consensus recommendation of “Buy” from the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, ten have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $107.00.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen lowered shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Morgan Stanley initiated coverage on shares of Monopar Therapeutics in a research note on Friday, January 9th. They issued an “overweight” rating and a $115.00 target price for the company. Chardan Capital reissued a “buy” rating and set a $100.00 target price on shares of Monopar Therapeutics in a research report on Monday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, January 21st.

Monopar Therapeutics News Roundup

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: Chardan Capital reaffirmed its Buy rating and maintains a $100 price target, signaling continued confidence from at least one boutique healthcare analyst and supporting upside expectations. Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics
• Positive Sentiment: HC Wainwright raised its medium-to-long-term earnings outlook for Monopar: FY2028 improved to ($0.54) from ($0.85), FY2029 to $1.79 (up from -$0.07), and FY2030 to $4.38 — suggesting the firm sees meaningful revenue/profit inflection later in the decade. This supports a longer-term bull case if pipeline and commercial execution materialize. HC Wainwright updates Monopar estimates
• Negative Sentiment: HC Wainwright materially lowered near-term EPS forecasts across 2026: Q1 to ($0.77) from ($0.55), Q2 to ($0.82) from ($0.58), Q3 to ($0.91) from ($0.65), Q4 to ($1.02) from ($0.73), and cut FY2026 to ($3.53) from ($2.52). These downgrades imply bigger-than-expected cash burn or delays in revenue/timing and are likely to pressure the stock in the short term. HC Wainwright lowers near-term estimates for Monopar
• Neutral Sentiment: Context: consensus full-year EPS remains around ($1.65), while HC Wainwright’s FY2026 view is much more negative. Monopar recently missed Q1 results (reported -$0.61 vs. -$0.51 expected), which likely contributed to the bearish revisions. These factors create volatility — near-term downside risk but a clearer long-term recovery path per some analysts. Benzinga report on Chardan and Monopar

Hedge Funds Weigh In On Monopar Therapeutics

Several hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics during the 3rd quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics during the 2nd quarter valued at about $34,000. BNP Paribas Financial Markets increased its holdings in shares of Monopar Therapeutics by 100.6% in the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new position in shares of Monopar Therapeutics in the fourth quarter valued at about $65,000. Finally, JPMorgan Chase & Co. raised its stake in shares of Monopar Therapeutics by 1,821.0% in the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after purchasing an additional 1,821 shares during the last quarter. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $54.79 on Wednesday. Monopar Therapeutics has a 1-year low of $26.06 and a 1-year high of $105.00. The business has a fifty day moving average price of $58.98 and a 200-day moving average price of $71.03. The stock has a market capitalization of $366.55 million, a price-to-earnings ratio of -30.10 and a beta of 1.58.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Friday, March 27th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.10). On average, equities research analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.